Private company

NeuBase Therapeutics, Inc.

American pharmaceutical preparations company based in Pittsburgh2

In its 2022 annual report the company says: “NeuBase Therapeutics, Inc. is a biotechnology company focused on significantly reducing the burden of untreatable morbidity and mortality across the globe caused by rare and common diseases.”61

Last updated Oct 20, 2026.

Overview

-$33.8MNet income, fiscal 20223
  • IndustryPharmaceutical Preparations2
  • HeadquartersNew York, United States2
  • Incorporated inDE4
  • Business address350 Technology Drive, Pittsburgh, Pa 152194
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI529900RHAZB85RGSJZ732
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 55272702

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-145.6%Return on equity3
-$29.5MFree cash flow3

Financial statements

Operating income567893-$33.3M in 2022+87% since 2015
-$40.0M-$30.0M-$20.0M-$10.0M02015: -$17.8M-$17.8M20152016: -$24.6M-$24.6M2016+38%2017: -$23.8M-$23.8M2017−3%2018: -$13.9M-$13.9M2018−42%2019: -$25.5M-$25.5M2019+83%2020: -$17.1M-$17.1M2020−33%2021: -$26.6M-$26.6M2021+56%2022: -$33.3M-$33.3M2022+25%
Net income567893-$33.8M in 2022+122% since 2015
-$40.0M-$30.0M-$20.0M-$10.0M02015: -$15.2M-$15.2M20152016: -$25.8M-$25.8M2016+70%2017: -$23.8M-$23.8M2017−8%2018: -$13.2M-$13.2M2018−44%2019: -$26.1M-$26.1M2019+97%2020: -$17.4M-$17.4M2020−33%2021: -$25.4M-$25.4M2021+46%2022: -$33.8M-$33.8M2022+33%
Fiscal year20152016201720182019202020212022
Research and development$8.8M5$16.5M6$17.4M7$4.3M7$3.4M8$6.9M9$11.5M3$21.4M3
Operating expenses$33.3M3
Operating income-$17.8M5-$24.6M6-$23.8M7-$13.9M7-$25.5M8-$17.1M9-$26.6M3-$33.3M3
Interest$6.0K12$129.0K8$7.7K9$32.3K3$24.0K3
Income tax-$23.8M7-$13.2M7$013
Net income-$15.2M5-$25.8M6-$23.8M7-$13.2M7-$26.1M8-$17.4M9-$25.4M3-$33.8M3
Earnings per share-$0.899-$0.933-$1.043
Earnings per share (diluted)-$0.899-$0.933-$1.043
Shares (weighted, basic)32.5M shares3
Shares (weighted, diluted)32.5M shares3

Compare NeuBase Therapeutics, Inc. with another company

Corporate structure

NeuBase Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NeuBase Therapeutics, Inc.

  • GREENLIGHT CAPITAL INC Filed SC 13G/A on NeuBase Therapeutics, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2022)
  • Symetryx Corp Filed SC 13D/A on NeuBase Therapeutics, Inc., latest Sep 20, 2023 (3 filings since Aug 31, 2023)
  • Kershner Trading Americas,LLC Filed SC 13G/A on NeuBase Therapeutics, Inc., latest Jan 27, 2023
  • NeuBase Therapeutics, Inc. New York, New York, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NeuBase Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.5M3 Sep 30, 2022$3.0M3 Sep 30, 2021+15.2%
Accumulated depreciation$1.3M3 Sep 30, 2022$533.5K3 Sep 30, 2021+142.9%
Property and equipment, net$2.2M3 Sep 30, 2022$2.5M3 Sep 30, 2021−12.5%
Finance-lease assets$103.5K3 Sep 30, 2022$216.5K3 Sep 30, 2021−52.2%
Operating-lease assets (leased space)$5.6M3 Sep 30, 2022$5.9M3 Sep 30, 2021−5.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$23.2M3 Sep 30, 2022$52.9M3 Sep 30, 2021−56.2%
Long-term investments$03 Sep 30, 2022$415.7K3 Sep 30, 2021−100.0%

Leadership

Who has led NeuBase Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Irach B. Taraporewala2013–2015
  2. Samuel Backenroth2013
  3. Jason Scott Slakter2015–2017

Chair

  1. Ira A. Greenstein2013

President

  1. Irach B. Taraporewala2013–2014

Chief financial officer

  1. Samuel Backenroth2014–2020
  2. Todd P. Branning2022–2023

Chief operating officer

  1. William Roland Mann2020–2022
201520202025
Board members and other officers (17)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorDietrich Stephan named Jul 7, 202338

Former names

  • Ohr Pharmaceutical IncAug 26, 2009 to Jul 12, 20194
  • BBM HOLDINGS, INC.Apr 5, 2007 to Aug 17, 20094
  • PRIME RESOURCE INCMay 16, 2002 to Mar 23, 20074

Timeline

  1. Jan 7, 20258-K Executive or director change; Other events39
  2. Jun 27, 20248-K Change to shareholders' rights; Executive or director change; Shareholder vote40
  3. May 31, 20248-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights41
  4. May 22, 20248-K Shareholder vote42
  5. May 13, 20248-K Shareholder vote43
  6. May 3, 20248-K Listing notice or transfer44
  7. Apr 5, 20248-K Listing notice or transfer; Other events45
  8. Mar 7, 20248-K Other events46
  9. Feb 23, 20248-K Other events47
  10. Jan 26, 20248-K Entered a material agreement48
  11. Jan 17, 20248-K Executive or director change49
  12. Dec 28, 20238-K Ended a material agreement50
  13. Nov 4, 2015New chief executive Jason Scott Slakter becomes CEO14
  14. Jun 24, 2013New chief executive Samuel Backenroth becomes CEO16
  15. Jun 24, 2013New chief executive Irach B. Taraporewala becomes CEO15

Calendar

When it reported results

  1. May 11, 2023Reported quarterly or annual results51
  2. Feb 14, 2023Reported quarterly or annual results52
  3. Dec 21, 2022Reported quarterly or annual results53
  4. Aug 11, 2022Reported quarterly or annual results54
  5. May 12, 2022Reported quarterly or annual results55
  6. Feb 11, 2022Reported quarterly or annual results56
  7. Dec 23, 2021Reported quarterly or annual results57

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

129 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 44 major events, 29 insider forms, 6 large holders, 1 private raises, 39 other. The latest 20:

  1. Jan 13, 202515-12G EDGAR
  2. Jan 7, 20258-K EDGAR
  3. Jul 2, 2024EFFECT EDGAR
  4. Jul 2, 2024EFFECT EDGAR
  5. Jun 27, 202415-12G EDGAR
  6. Jun 27, 2024S-8 POS EDGAR
  7. Jun 27, 2024S-8 POS EDGAR
  8. Jun 27, 2024S-8 POS EDGAR
  9. Jun 27, 2024S-8 POS EDGAR
  10. Jun 27, 2024S-8 POS EDGAR
  11. Jun 27, 2024POS AM EDGAR
  12. Jun 27, 2024POS AM EDGAR
  13. Jun 27, 20248-K EDGAR
  14. Jun 3, 2024DEFA14A EDGAR
  15. May 31, 20248-K EDGAR
  16. May 22, 20248-K EDGAR
  17. May 16, 202425-NSE EDGAR
  18. May 14, 2024DEFA14A EDGAR
  19. May 13, 20248-K EDGAR
  20. May 6, 2024DEFA14A EDGAR

The 129 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

14 open-market trades by officers, directors and large owners since October 2021: 8 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 18, 2023Symetryx CorpSale50,000$1.19$59.5KForm 4
Sep 15, 2023Symetryx CorpSale103,337$1.26$130.2KForm 4
Sep 14, 2023Symetryx CorpSale129,108$1.44$185.9KForm 4
Sep 11, 2023Symetryx CorpSale3,376$1.44$4.9KForm 4
Sep 8, 2023Symetryx CorpSale128,847$1.53$197.1KForm 4
Sep 7, 2023Symetryx CorpSale74,852$1.80$134.7KForm 4
Sep 1, 2023Symetryx CorpBuy61,076$0.98$59.9KForm 4
Mar 30, 2022Mann William RolandChief Operating OfficerBuy6,200$1.92$11.9KForm 4
Mar 18, 2022Branning Todd P.Chief Financial OfficerBuy10,000$1.81$18.1KForm 4
Mar 17, 2022Branning Todd P.Chief Financial OfficerBuy10,000$1.74$17.4KForm 4
Mar 16, 2022Branning Todd P.Chief Financial OfficerBuy10,000$1.62$16.2KForm 4
Mar 4, 2022RICHMAN ERIC IDirectorBuy1,000$1.62$1.6KForm 4
Mar 3, 2022RICHMAN ERIC IDirectorBuy1,300$1.72$2.2KForm 4
Mar 1, 2022RICHMAN ERIC IDirectorBuy1,580$1.58$2.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jun 28, 2023Raised $5 million in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How NeuBase Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNeuBase Therapeutics, Inc.1
  • CIK0001173281
  • Employer ID (EIN)46-56224331
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address350 Technology Drive, Pittsburgh, PA 152191
  • Phone412-763-33501
  • Shares outstanding3,729,206 as of Nov 6, 202311
  • Public float$57.9M as of Mar 31, 20223
  • On EDGAR sinceMay 16, 20021
  • Filings670 in all: 8-K (199), 4 (110), 10-Q (47), UPLOAD (25), CORRESP (24), 3 (22), 10QSB (16), 10-K (15)1
    All 51 form types

    424B5 (14), SC 13G (13), SC 13G/A (13), 8-K/A (12), DEF 14A (11), DEFA14A (11), NT 10-Q (11), EFFECT (10), NT 10-K (10), 425 (9), SB-2/A (8), D (7), 10-K/A (6), 10-Q/A (6), 424B3 (6), S-3 (6), 10KSB (5), 10QSB/A (5), S-8 (5), S-8 POS (5), PRE 14A (4), S-4/A (4), SC 13D (3), SC 13D/A (3), 15-12G (2), 4/A (2), 5 (2), CT ORDER (2), POS AM (2), S-3/A (2), 10-QT (1), 10KSB/A (1), 25-NSE (1), 3/A (1), 8-A12B (1), ARS (1), CERTNAS (1), REGDEX/A (1), S-1 (1), S-3MEF (1), S-4 (1), SB-2 (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Dec 21, 2022
    Quarterly report (10-Q) Nov 9, 2023
    Proxy statement (DEF 14A) Apr 9, 2024
    Latest 8-K (8-K) Jan 7, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
    SEC EDGAROther events
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61